ACE723 / Acepodia - LARVOL DELTA

Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate (PRNewswire) - "The clearance enables Acepodia to advance ACE723 into Phase 1 clinical development....The planned Phase 1 study will evaluate the safety, tolerability, dose-limiting toxicities, pharmacokinetics and preliminary anti-tumor activity of ACE723 in patients with unresectable or metastatic HCC. The dose-escalation portion of the study is expected to characterize the safety profile and establish a recommended dose for subsequent clinical development and potential expansion cohorts. Acepodia also submitted an IND application for ACE723 to China's National Medical Products Administration (NMPA) in August 2026 as part of the Company's global development strategy for the program."

IND • New P1 trial • Hepatocellular Cancer

Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment (AACR 2025) - "The HCC xenograft study further demonstrated that the anti-GPC3 AD2C completely suppressed tumor growth at doses of up to 10 mg/kg, with no significant body weight change observed. In conclusion, the dual-payload ADC produced by AD2C platform offers a potential strategy to overcome tumor heterogeneity and drug resistance while maintaining an ideal safety profile, supporting its potential clinical application in HCC treatment."

ADC • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025 (PRNewswire) - "The poster presentation, titled 'Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment,' showcases the company's next-generation ADC generated using Acepodia's AD2C platform. This platform allows for the conjugation of two distinct payloads to a single antibody without the need of antibody engineering or enzymatic conjugation. AD2C, carrying payloads with different mechanisms of action, offer enhanced therapeutic potency by targeting diverse cell populations in heterogeneous tumors or overcoming resistance to single-payload therapy."

Preclinical • Hepatocellular Cancer